 In 2010, ACT received approval from the Food and Drug Administration for clinical trials of a pluripotent stem cell-based treatment for use in people with degenerative eye diseases.In 2011 ACT received approval from the Medicines and Healthcare products Regulatory Agency to use its PSC-based cell therapy in the UK; this was the first approval to study a PSC-based treatment in Europe.The first person received the embryonic stem cell treatment in the UK in 2012.